Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Seproxetine
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 4–16 days |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H16F3NO |
Molar mass | 295.305 g·mol−1 |
Seproxetine, also known as (S)-norfluoxetine, is a selective serotonin reuptake inhibitor (SSRI). It is the S enantiomer of norfluoxetine, the main active metabolite of the widely used antidepressant fluoxetine; but little is known about its pharmacological actions. Seproxetine was being investigated by Eli Lilly and Company as an antidepressant; however, cardiac side effects were discovered and development was discontinued.
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
|
5-HT1AR agonists | |
---|---|
GABAAR PAMs |
|
Gabapentinoids |
|
Antidepressants |
|
Sympatholytics |
|
Others | |
|
DAT (DRIs) |
|
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NET (NRIs) |
|
||||||||||||||
SERT (SRIs) |
|
||||||||||||||
VMATs | |||||||||||||||
Others |
|
||||||||||||||
Corporate directors | |
---|---|
Products |
|